The Lexaria study comparing two oral DehydraTECH-semaglutide formulations with Novo Nordisk’s Wegovy tablets has reached full enrollment, Lexaria Bioscience announced on October 21, 2026. Dosing remains on schedule, with the final group expected to finish in mid-November before laboratory analyses and reporting.
Key Takeaways
- Full enrollment marks a study milestone, not a finding on safety or drug absorption.
- The three-arm trial compares DehydraTECH tablet and capsule formulations with Wegovy tablets.
- Lexaria says the study is fully funded from existing corporate resources.
Table of Contents
- Lexaria study moves toward November dosing completion
- Tablet format and repeated dosing distinguish the trial
- Conclusion
Lexaria study moves toward November dosing completion
Lexaria’s enrollment and dosing update states that the final study arm began dosing in early October 2026. The company plans to provide another progress update once all dosing is complete.
The five-week Human Pilot Study #7, also identified as GLP-1-H26-7, assesses safety, tolerability and pharmacokinetic properties—how the drug enters and moves through the body. The announcement does not provide comparative results or establish that either experimental formulation performs better than Wegovy.
Laboratory sample analyses and reporting will follow dosing completion. Lexaria did not specify a date for releasing those results.
| Item | Details |
|---|---|
| Study identifier | Human Pilot Study #7, GLP-1-H26-7 |
| Administration conditions | Fasted before dosing |
| Experimental treatments | SNAC-inclusive DehydraTECH-semaglutide tablet and capsule |
| Comparator | Commercially available Wegovy tablets |
Tablet format and repeated dosing distinguish the trial
For the first time in its DehydraTECH GLP-1 studies, Lexaria is testing an oral tablet rather than only capsules. The company says the tablet incorporates certain physical properties of Novo Nordisk’s oral semaglutide delivery approach.
Both experimental formulations include SNAC, a component used in the oral semaglutide delivery formulations described by Lexaria. The company’s earlier SNAC-inclusive human pilot studies in 2024 and 2025 used single doses and did not test tablets.
The five-week schedule is intended to allow semaglutide concentrations to reach steady state, when drug intake and the body’s elimination of the drug come into balance. That design allows researchers to examine repeated dosing rather than only the response to one dose.
Conclusion
The next announced milestone is completion of dosing, expected in mid-November 2026, followed by a company progress update. Comparative findings remain pending laboratory analysis and reporting.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
